Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting

Kaboré, Nongodo Firmin; Poda, Armel; Zoungrana, Jacques; Da, Ollo; Ciaffi, Laura; Semde, A.; Yaméogo, Issouf; Sawadogo, Adrien; Delaporte, Éric; Méda, Nicolas; Limou, Sophie; Cournil, Amandine

doi:10.1186/s12882-019-1335-9

Cited by 34 publications

(26 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to treated hypertensive patients, those newly diagnosed with hypertension are more likely to have lived with the disease for a shorter duration; and as a result, are less likely to develop CKD. The prevalence of CKD in PLWHA was 3%, which was comparable to the findings of Kabore and colleagues [ 51 ]. We observed a prevalence of CKD among persons living with diabetes mellitus of 18.7%.…”

Section: Discusssionsupporting

confidence: 87%

Chronic kidney disease in Cameroon: a scoping review

Aseneh

Kemah

Mabouna³

et al. 2020

BMC Nephrol

View full text Add to dashboard Cite

Objectives This scoping review sought to summarize available data on the prevalence, associated factors, etiology, comorbidities, treatment, cost and mortality of chronic kidney disease (CKD) in Cameroon. Methods We searched PubMed, Scopus and African Journals Online from database inception to 31 March, 2020 to identify all studies published on the prevalence, associated factors, etiology, comorbidities, treatment, cost and mortality of CKD in Cameroon. Results Thirty studies were included. The prevalence of CKD varied from 3 to 14.1 and 10.0%–14.2% in rural and urban areas, respectively. The prevalence of CKD in patients with hypertension, diabetes mellitus, and human immunodeficiency virus was 12.4–50.0, 18.5%, and 3.0–47.2%, respectively. Hypertension (22.3–59.1%), chronic glomerulonephritis (15.8–56.2%), and diabetes mellitus (15.8–56.2%) were the most common causes of CKD. The cause was unknown in 13.5–17.0% of the cases. Advanced age, hypertension, diabetes mellitus, and obesity were frequent associated factors. Hemodialysis was the main treatment modality in patients with End Stage Renal Disease (ESRD). The monthly cost of management of non-dialyzed CKD was 163 US dollars. The one-year mortality rate of ESRD was 26.8–38.6%. Conclusion Chronic kidney disease affects about one in 10 adults in the general population in Cameroon. Patients with hypertension, diabetes mellitus, and human immunodeficiency virus bear the greatest burden of CKD in Cameroon. Advanced age, hypertension, diabetes mellitus, and obesity are major factors associated with CKD. Chronic kidney disease in Cameroon is associated with high morbidity and mortality and huge economic cost on the patient.

show abstract

Section: Discusssionsupporting

confidence: 87%

Chronic kidney disease in Cameroon: a scoping review

Aseneh

Kemah

Mabouna³

et al. 2020

BMC Nephrol

View full text Add to dashboard Cite

show abstract

“…Compared to patients with hypertension and who are on treatment, those newly diagnosed with hypertension are more likely to have had the disease for a relatively shorter time, and hence experience a lesser burden of the disease on the kidneys. The prevalence of CKD in PLWHA was 3%, comparable to that of PLWHA in another West African setting [52]. In a systematic review in Africa, the prevalence of CKD among diabetics varied between 11% and 83.7% [53], a range which includes the 18.7% in type 2 diabetics in our setting.…”

Section: Discussionsupporting

confidence: 55%

Chronic Kidney Disease in Cameroon: A scoping review

Aseneh¹,

Kemah²,

Mabouna³

et al. 2020

Preprint

View full text Add to dashboard Cite

ObjectivesThis scoping review sought to summarize available data on the prevalence, associated factors, etiology, comorbidities, treatment, cost, and mortality of chronic kidney disease (CKD) in Cameroon.MethodsWe searched PubMed, Scopus and African Journals Online from database inception to 31 March, 2020 to identify all studies published on the prevalence, associated factors, etiology, comorbidities, treatment, cost and mortality of CKD in Cameroon.ResultsThirty studies were included. The population prevalence of CKD varied from 3-14.1% and 10.0%-14.2% in rural and urban areas, respectively. The prevalence of CKD in patients with hypertension, diabetes mellitus, and human immunodeficiency virus was 12.4-50.0%, 18.5%, and 3.0-47.2%, respectively. Hypertension (22.3-59.1%), chronic glomerulonephritis (15.8-56.2%), and diabetes mellitus (15.8-56.2%) were the most common causes of CKD. The cause was unknown in 13.5-17.0% of the cases. Advanced age, hypertension, diabetes mellitus, and obesity were frequent associated factors. Hemodialysis was the main treatment modality in patients with End Stage Renal Disease (ESRD). The monthly cost of management of non-dialyzed CKD was 163 US dollars. The one-year mortality rate of ESRD was 26.8-38.6%.ConclusionChronic kidney disease in affects about one in ten adults in the general population in Cameroon Patients with hypertension, diabetes mellitus, and human immunodeficiency virus bear the greatest burden of CKD in Cameroon. Advanced age, hypertension, diabetes mellitus, and obesity are major factors associated with CKD. Chronic kidney disease in Cameroon is associated with high morbidity and mortality and huge economic cost on the patient.

show abstract

“…Miscalibration of the model with overall under‐estimation could also indicate that other important risk factors are missing and hypertension is one of them. In a recent study conducted in people initiating ART in the Bobo Dioulasso clinic, we found that hypertension was strongly associated with progression to CKD [14]. Another risk factor to consider is the APOL1‐linked genetic predisposition.…”

Section: Discussionmentioning

confidence: 99%

Validation of the D:A:D chronic kidney disease risk score in people living with HIV: the IeDEA West Africa Cohort Collaboration

et al. 2020

View full text Add to dashboard Cite

ObjectivesA risk score for long‐term prediction of chronic kidney disease (CKD) in people living with HIV (PLHIV) has been developed using data from the D:A:D cohort. We assessed the performance of the D:A:D risk score in a cohort of PLHIV in West Africa.MethodsData from PLHIV starting antiretroviral treatment in four clinics in Burkina Faso, Côte d’Ivoire and Togo participating in the IeDEA West Africa collaboration were analysed. CKD was defined as two consecutive estimated glomerular filtration rates (eGFRs) of ≤ 60 mL/min/1.73 m2. The D:A:D score (short version) was calculated using age, gender, nadir CD4 and baseline eGFR and was categorized into low, medium, and high‐risk groups.ResultsIn 14 930 participants (70% female, median age = 38 years; median nadir CD4 count = 183 cells/µL) followed for a median duration of 5.7 years, 660 (4.4%) progressed to CKD, with an incidence [95% confidence interval (CI)] of 7.8 (7.2–8.4) per 1000 person‐years (PY). CKD incidence rates were 2.4 (2.0–2.8), 8.1 (6.8–9.6) and, 30.9 (28.0–34.1) per 1000 PY in the low‐, medium‐ and high‐risk groups, respectively. In the high‐risk group, 14.7% (95% CI: 13.3; 16.3) had progressed to CKD at 5 years. Discrimination was good [C‐statistics = 0.81 (0.79–0.83)]. In all, 79.4% of people who progressed to CKD were classified in the medium‐ to high‐risk group at baseline (sensitivity) and 66.5% of people classified in the low risk group at baseline did not progress to CKD (specificity).ConclusionsThese findings confirm the validity of the D:A:D score in identifying individuals at risk of developing CKD who could benefit from enhanced kidney monitoring in West African HIV clinics.

show abstract

Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting

Cited by 34 publications

References 48 publications

Chronic kidney disease in Cameroon: a scoping review

Chronic kidney disease in Cameroon: a scoping review

Chronic Kidney Disease in Cameroon: A scoping review

Validation of the D:A:D chronic kidney disease risk score in people living with HIV: the IeDEA West Africa Cohort Collaboration

Contact Info

Product

Resources

About